Sudarshan Pharma Industries Ltd — Important, 14-08-2026: Company Update

Sudarshan Pharma presented details on a proposed acquisition of a USFDA-approved manufacturing unit. This 14-acre plant near Visakhapatnam produces Active Pharmaceutical Ingredients (APIs) and intermediates, holding approvals from USFDA, WHO Geneva, and ANVISA. With a total capacity of 584 KL across four blocks, it caters to various therapeutic categories, including Lamivudine API. This move is expected to significantly boost Sudarshan Pharma's manufacturing capabilities and expand its product reach within both domestic and international pharmaceutical markets.